The global generics pharmaceutical market has become an intimidating segment of the pharmaceutical drug market which continuously growing and increasing with its accessibility & benefits offered as efficient and economical drugs. Generics are approved copies of small molecule drugs that contain the same amount of active ingredients, dosage form, safety, strength, route of administration, quality, […]Read More
AstraZeneca’s Brilinta (ticagrelor) Receives the US FDA’s Approval to Reduce the Risk of Stroke in Patients with an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Published: Nov 6, 2020 | Tags: AstraZeneca, Brilinta, ticagrelor, Receives, US FDA, Approval, Acute, High,Risk, Transient, Ischaemic, Stroke Novo Nordisk to Acquire Emisphere Technologies for $1.8B Published: Nov 6, […]Read More
Shots: The P-III extension studies (reSURFACE 1 & reSURFACE 2) involves assessing Ilumya (100 & 200mg) vs PBO in moderate-to-severe PsO participants with at least 50% improvement in PASI 50 at base study completion who received Ilumya within 12wks. of base study end (52 or 64wks.) were eligible to enroll in the extension study & continued […]Read More
1. Ultragenyx and Kyowa Kirin’s Crysvita (burosumab) Receive the US FDA’s Approval for the Treatment of Tumor-Induced Osteomalacia Published: Jun 19, 2020 | Tags: Ultragenyx, Kyowa Kirin, Crysvita, burosumab, Receives, US, FDA, Approval, Treatment, Tumor-Induced Osteomalacia 2. Pfizer and Sangamo’s Giroctocogene Fitelparvovec (SB-525) Demonstrate Positive Effect in P-I/II Alta Study for Hemophilia A Published: Jun 18, 2020 […]Read More
Shots: SunPharma to receive upfront and milestones for licensing its product to Hikma and will supply Ilumya. Hikma will be responsible for the registration and commercialization of the product in all MENA markets Hikma’s presence in the MENA region will enable access to a new treatment option for people who are unable to manage their […]Read More
1. Arena’s APD418 Receives FDA’s Fast Track Designation to Treat Patients with Decompensated Heart Failure Published: Jan 17, 2020 | Tags: Arena, APD418, Receives, FDA, Fast Track Designation, Treat, Patients, Decompensated Heart 2. Charles River Collaborates with Fios Genomics for Bioinformatics-Driven Drug Discovery and Safety Assessment Published: Jan 16, 2020 | Tags: Charles River, Collaborates, Fios Genomics, […]Read More
Shots: Rockwell to receive up front, milestones and royalties on sales of Triferic. Sun Pharma to get an exclusive right to develop & commercialize Triferic, following its approval in India Sun Pharma will be responsible for all clinical, regulatory and commercialization activities of Triferic in India. The collaboration allows Sun Pharma to expand its portfolio […]Read More
1. Johnson & Johnson Initiates Voluntarily Recall of a Single Lot of its Baby Powder in the US Published: Oct 18, 2019 | Tags: JnJ, Initiates, Voluntarily, Recall, Baby Powder, US 2. AbbVie’s Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate to Severe Active Rheumatoid Arthritis Published: Oct 18, 2019 | Tags: AbbVie, Rinvoq, Upadacitinib, Receives, […]Read More
Shots: The launch of Drizalma Sprinkle expands Sun Pharma’s portfolio of an alternative formulation designed for patients with swallowing difficulties, following its Ezallor Sprinkle (Rosuvastatin) and Kapspargo Sprinkle (metoprolol succinate) extended-release capsules, marking it as the third product of Sun Pharma’s portfolio In July’2019, the US FDA has approved Drizalma Sprinkle and is an important […]Read More
Shots: The P-III reSURFACE 1 and 2 are extension-study involves assessing of Ilumya (100 &200 mg at 0 and 4wks.) and Ilumya (100 & 200 mg) vs PBO and etanercept (50 mg) respectively. The reSURFACE 1 and reSURFACE 2 Post-Hoc Analyses was conducted to evaluate changes in efficacy of Ilumya in patients with/out metabolic syndrome […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
